Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Medical Laboratory Sciences, Varastegan Institute for Medical Sciences, Mashhad, Iran; Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Mult Scler Relat Disord. 2024 Feb;82:105401. doi: 10.1016/j.msard.2023.105401. Epub 2023 Dec 22.
Multiple sclerosis (MS) is a complex central nervous system disorder, marked by neurodegenerative and inflammatory processes, where overproduction of reactive oxygen species (ROS) is a key factor in demyelination and neurodegeneration. The current study aims to investigate the effect of hesperidin and Quinolinic acid (QA) on ROS and antioxidant levels, and cell viability of OLN-93 cells.
OLN-93 cell lines were treated with hesperidin and QA. OLN-93 cells were cultured in Dulbecco's modified Eagle's medium under controlled conditions. Cell viability assays were performed using resazurin to assess the toxicity of hesperidin and QA. Additionally, ROS levels were measured using DCFDA, and malondialdehyde (MDA) levels were determined to evaluate oxidative stress. Superoxide dismutase (SOD) activity and cell viability were assessed by trypan blue staining after exposure to hesperidin and QA.
The results of the current study showed that co-administration of 8 mM QA with 50, 100, and 200 μM hesperidin significantly reduced both ROS and MDA levels, demonstrating a substantial attenuation in comparison to the elevated ROS and MDA levels induced by 8 mM QA (p-value < 0.01). Furthermore, 8 mM QA + 50, 100, and 200 μM hesperidin significantly increased SOD levels compared with QA alone (p-value < 0.01). In addition, treatment of OLN cells with 8 mM QA + 50, 100, and 200 μM hesperidin led to higher cell viability compared to QA alone (p value <0.0001).
The current study demonstrated the antioxidant effect of hesperidin on OLN-93 cells suggesting new insights into the clinical application of hesperidin as an effective treatment for patients with MS. Future in vivo studies, focusing on cellular mechanisms are recommended.
多发性硬化症（MS）是一种复杂的中枢神经系统疾病，其特征为神经退行性和炎症过程，其中活性氧（ROS）的过度产生是脱髓鞘和神经退行性变的关键因素。本研究旨在探讨橙皮苷和喹啉酸（QA）对 OLN-93 细胞 ROS 和抗氧化剂水平及细胞活力的影响。
用橙皮苷和 QA 处理 OLN-93 细胞系。OLN-93 细胞在控制条件下于 Dulbecco 改良 Eagle 培养基中培养。使用 Resazurin 进行细胞活力测定，以评估橙皮苷和 QA 的毒性。此外，使用 DCFDA 测量 ROS 水平，并用 MDA 水平评估氧化应激。用橙皮苷和 QA 处理后，通过台盼蓝染色评估超氧化物歧化酶（SOD）活性和细胞活力。
本研究结果表明，8 mM QA 与 50、100 和 200 μM 橙皮苷联合给药可显著降低 ROS 和 MDA 水平，与 8 mM QA 诱导的升高的 ROS 和 MDA 水平相比，显著降低（p 值<0.01）。此外，与单独使用 QA 相比，8 mM QA+50、100 和 200 μM 橙皮苷可显著提高 SOD 水平（p 值<0.01）。此外，与单独使用 QA 相比，用 8 mM QA+50、100 和 200 μM 橙皮苷处理 OLN 细胞可提高细胞活力（p 值<0.0001）。
本研究表明橙皮苷对 OLN-93 细胞具有抗氧化作用，提示橙皮苷作为 MS 患者有效治疗方法的临床应用有新的见解。建议开展关注细胞机制的未来体内研究。
